A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

The FDA on Tuesday handed down an accelerated approval for CTI BioPharma’s JAK inhibitor Vonjo (pacritinib) to treat intermediate or high-risk primary or secondary myelofibrosis with a platelet count below 50 × 109/L, the company said in a release.